These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma. Gao Z; Man X; Li Z; Bi J; Liu X; Li Z; Zhu Y; Zhang Z; Kong C Oncol Rep; 2019 Apr; 41(4):2440-2452. PubMed ID: 30816525 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA expression patterns associated with hyperfunctioning and non-hyperfunctioning phenotypes in adrenocortical adenomas. Velázquez-Fernández D; Caramuta S; Özata DM; Lu M; Höög A; Bäckdahl M; Larsson C; Lui WO; Zedenius J Eur J Endocrinol; 2014 Apr; 170(4):583-91. PubMed ID: 24446485 [TBL] [Abstract][Full Text] [Related]
13. Identification of differentially expressed microRNA in parathyroid tumors. Rahbari R; Holloway AK; He M; Khanafshar E; Clark OH; Kebebew E Ann Surg Oncol; 2011 Apr; 18(4):1158-65. PubMed ID: 21086055 [TBL] [Abstract][Full Text] [Related]
14. MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors. Patel D; Boufraqech M; Jain M; Zhang L; He M; Gesuwan K; Gulati N; Nilubol N; Fojo T; Kebebew E Surgery; 2013 Dec; 154(6):1224-8; discussion 1229. PubMed ID: 24238045 [TBL] [Abstract][Full Text] [Related]
15. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling. Suh I; Shibru D; Eisenhofer G; Pacak K; Duh QY; Clark OH; Kebebew E Ann Surg; 2009 Dec; 250(6):983-90. PubMed ID: 19661783 [TBL] [Abstract][Full Text] [Related]
16. Expression of Wnt and TGF-β pathway components and key adrenal transcription factors in adrenocortical tumors: association to carcinoma aggressiveness. Parviainen H; Schrade A; Kiiveri S; Prunskaite-Hyyryläinen R; Haglund C; Vainio S; Wilson DB; Arola J; Heikinheimo M Pathol Res Pract; 2013 Aug; 209(8):503-9. PubMed ID: 23866946 [TBL] [Abstract][Full Text] [Related]
17. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Fonseca AL; Kugelberg J; Starker LF; Scholl U; Choi M; Hellman P; Åkerström G; Westin G; Lifton RP; Björklund P; Carling T Genes Chromosomes Cancer; 2012 Oct; 51(10):949-60. PubMed ID: 22733721 [TBL] [Abstract][Full Text] [Related]
18. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors. Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715 [TBL] [Abstract][Full Text] [Related]
19. Identification of novel lipid metabolic biomarkers associated with poor adrenocortical carcinoma prognosis using integrated bioinformatics. Subramanian C; Cohen MS Surgery; 2022 Jan; 171(1):119-129. PubMed ID: 34353633 [TBL] [Abstract][Full Text] [Related]
20. Nephroblastoma overexpressed/cysteine-rich protein 61/connective tissue growth factor/nephroblastoma overexpressed gene-3 (NOV/CCN3), a selective adrenocortical cell proapoptotic factor, is down-regulated in childhood adrenocortical tumors. Doghman M; Arhatte M; Thibout H; Rodrigues G; De Moura J; Grosso S; West AN; Laurent M; Mas JC; Bongain A; Zambetti GP; Figueiredo BC; Auberger P; Martinerie C; Lalli E J Clin Endocrinol Metab; 2007 Aug; 92(8):3253-60. PubMed ID: 17566092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]